Discovery and Development of Small-Molecule Antitumor Drugs
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 7522
Special Issue Editors
Interests: targeted therapy; small-molecule medicine; immunotherapy; drug resistance; precision medicine; multiomics
Interests: discovery of small molecules; anti-tumor drugs targeting kinase, UPS and associated mechanisms
Special Issue Information
Dear Colleagues,
Cancer is the second-leading cause of death worldwide, and the global healthcare burden caused by cancer is immense. According to the WHO, over 19 million new cancer cases, and approximately 10 million cancer-related deaths occurred in 2020. The number of cancer cases is expected to increase by almost 50% by 2040. Drug treatment for cancers can be roughly classified into three categories: small molecules, macromolecules (such as monoclonal antibodies, polypeptides, antibody–drug conjugates, and nucleic acids), and cell-based immunotherapies (such as CAR-T cell therapy, CAR-NK cell therapy, and TCR-T cell therapy). Despite recent challenges by macromolecule drugs represented by monoclonal antibodies and cell-based immunotherapy, small-molecule targeted drugs still are still extensively developed due to their advantages, such as the pharmaco-kinetic (PK) properties, low cost, patient compliance, and drug storage and transportation. The object of this Special Issue is to provide an overview on recent trends in the discovery and development of small-molecule anti-tumor drugs.
We welcome high-quality reviews or research articles for this Special Issue. The topics of this Special Issue include, but are not limited to:
- Natural products;
- Kinase inhibitors;
- Small molecules targeting UPS (Ubiquitin-26S proteasome system);
- Epigenetic inhibitors;
- Small-molecule immuno-oncology therapeutic agents;
- Identification and validation of small-molecule anti-tumor drug targets.
Prof. Dr. Hubing Shi
Prof. Dr. Feng Wang
Dr. Haoyu Ye
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- small-molecule drugs
- anti-tumor
- natural products
- kinase inhibitors
- proteasome inhibitors
- epigenetic inhibitors
- immuno-oncology therapy
- targets identification
